Light therapy and methotrexate for psoriasis
Part of Immune system & allergy, Skin clinical trials.
This study tests whether combining narrowband UVB light therapy with methotrexate helps treat moderate to severe plaque psoriasis. It looks at a blood marker called gelsolin to see if treatment reduces inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate to severe plaque psoriasis (red, scaly patches on skin).
- You haven't used any systemic (pills or injections) or biologic (targeted immune) treatments for psoriasis in the last 3 months.
- You are not pregnant, breastfeeding, or planning to become pregnant.
- You do not have an active infection.
- You do not have liver disease, blood disorders, chronic kidney failure, or cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a specific gene change (called TRAF3IP2) in people with psoriasis or psoriatic arthritis who are about to start methotrexate. The goal is to see if the gene affects how well the treatment works or if it causes side effects.
This study tests whether narrowband ultraviolet B (UVB) light given three times a week for 12 weeks improves moderate-to-severe plaque psoriasis. It is an “open-label” pilot, meaning everyone gets the UVB treatment and researchers track how your skin responds.
This pilot study tests whether adding probiotics to standard methotrexate treatment improves symptoms in people newly diagnosed with chronic plaque psoriasis. It aims to see how the gut microbiome affects treatment response.
This study compares two systemic medications—methotrexate (a traditional immunosuppressant) and tofacitinib (a newer targeted therapy)—to see which works better for moderate-to-severe plaque psoriasis that hasn't responded well to creams or ointments.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This trial tests two oral medications, Apremilast and Methotrexate, to see which works better for people with moderate to severe plaque psoriasis. You must not have taken systemic treatments (pills or shots that work throughout the body) in the last 3 months.
Hear when a new Psoriatic Conditions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.